

European patient survey on CAR T-cell therapy to gain insights into patients' experiences, quality of life and unmet needs



After months of preparation in close collaboration with patient advocacy groups, patients and carers, the T2EVOLVE and QUALITOP consortia are proud to launch the **European patient survey on CAR T-cell therapy!** This survey will help to understand patients' experiences with CAR T-cell therapy, evaluate the impact of this treatment on the quality of life and identify unmet needs. With this information, we aim to improve quality of life in patients receiving CAR T-cell therapy and their carers by optimizing support and improving the CAR T-cell treatment journey.

All European adult patients (≥ 18 years) who received CAR T-cell therapy for a hematologic malignancy (no specific indication required) can participate by filling in a digital survey.

Now, we need you!

If you are a patient treated with CAR T-cell therapy for a hematologic malignancy in Europe we would like to invite you to share your experiences with us by participating in our survey!

The survey is available in English, French, German, Spanish, Italian, Portuguese and Dutch.

2 WAYS TO ACCESS & SHARE THE SURVEY

(before April 30, 2023)

<https://t2evolve.fyi/patientsurvey>



Password to enter the survey:
T2EVOLVE_QUALITOP